期刊文献+

LC-MS/MS法测定大鼠血浆中齐留通的含量及其药动学研究

An LC-MS/MS method for determining Zileuton in rat plasma and its pharmacokinetic properties
原文传递
导出
摘要 目的:建立测定大鼠血浆中齐留通含量的LC-MS/MS方法,研究齐留通片和齐留通原料在大鼠体内的药动学过程和生物利用度。方法:大鼠灌胃(ig)给药后,分别于不同时间点采血,血浆样品采用LC-MS/MS测定血药浓度,采用DAS 2.0软件求算药动学参数。结果:齐留通的血浆浓度在1~1 000 ng·mL^(-1)范围内线性关系良好(r=0.999 92),日间精密度和日内精密度RSD均小于15%,稳定性、回收率均在85%~115%。齐留通片和齐留通的半衰期分别为6.091和7.91 h,齐留通片在大鼠体内的相对生物利用度为138.90%。结论:该方法可用于测定大鼠血浆中齐留通的含量,齐留通片在大鼠体内吸收较好,本实验结果可为齐留通仿制药的研究提供依据。 Objective: To establish an LC-MS/MS method for determining Zileuton in rat plasma and study the pharmacokinetic properties of Zyflo and Zileuton. Methods: Rats recieved Zyfio and Zileuton by intragastrical administration, plasma samples were extracted at different time. Then the concentrations of Zileuton in plasma were determined. Pharmacokinetic parameters were calculated with DAS 2.0 software. Results: Calibration curve of Zileuton was linear in range of 1 - 1 000 ng·mL^-1(r =0.99992), RSD of intra- and inter-day were less than 15%. Extraction recoveries and stability were between 85% - 115%. t1/2 of Zyflo and Zileuton were 6. 091 h and 7.91 h, and the relative bioavailability value was 138.90%. Conclusion: The method is successfully applied for determining Zileuton in rat plasma. Zyflo can be obsorbed better in rat, which can be used for the determination o! generic drug study .
出处 《中国新药杂志》 CAS CSCD 北大核心 2017年第9期1042-1046,共5页 Chinese Journal of New Drugs
基金 国家自然科学基金资助项目(81374017)
关键词 LC-MS/MS 齐留通 药动学 LC-MS/MS Zileuton pharmacokinetics
  • 相关文献

参考文献3

二级参考文献19

  • 1夏璐,鲍英,袁耀宗,张学军.全反式维甲酸诱导胰腺癌细胞凋亡机制研究[J].中华消化杂志,2004,24(7):391-394. 被引量:14
  • 2宋娟,周彦彬,丁劲松.高效液相色谱法测定人血浆中齐留通[J].中南药学,2005,3(6):343-345. 被引量:1
  • 3NATHAN RA, PRENNER BM, BERNSTEIN JA, et al. Zileuton provides significant improvement in asthma symptoms and β- agonist and rescue medication use compared to placebo in asthma patients with reduced or low lung function [J]. J Allergy Clin Immunol, 2006,117(2 Suppl 1 ) : S156.
  • 4BERGER WE, MURRAY J J, GROSS GN, et al. Zileuton, 600 mg qid, provides early and sustained improvement in pulmonary function compared to placebo in moderate and severe asthmatic patients versus placebo [J]. J Allergy Clin Immunol , 2006, 117 (2 Suppl 1 ) : S5.
  • 5WONG SL, AWNI WM, CAVANAUGH JH, et al. The pharmacokinetics of single oral doses of zileuton 200 to 800 mg, its enantiomers, and its metabolites, in normal healthy volunteers[J]. Clin Pharmacokinet, 1995, 29 Suppl 2: 9-21.
  • 6AWNI WM, CAVANAUGH JH, WITT G, et al. The effect of food on the pharmacokinetics of zileuton[J]. Clin Pharmacokinet, 1995, 29 Suppl 2: 62-66.
  • 7AWNI WM, BRAECKMAN RA, GRANNEMAN GR, et al. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers[J]. Clin Pharmacokinet, 1995, 29Suppl 2:22-33.
  • 8QIU YH, CHESKIN H, BRISKIN J, et al. Sustained-release hydrophilic matrix tablets of zileuton: formulation and in vitro/ in vivo studies[J]. J Control Release, 1997, 45: 249-256.
  • 9Wang C G,Am Rev Respir Dis,1993年,148卷,413页
  • 10Hui K P,Lancet,1991年,337卷,1062页

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部